Literature DB >> 3132502

Protein phosphorylation mediated by IL-2/IL-2 receptor beta-chain interaction.

T Ishii1, T Takeshita, N Numata, K Sugamura.   

Abstract

We previously found that IL-2 rapidly induced protein phosphorylation of a 67-kDa (pp67) and four 63-kDa (pp63s) cellular proteins in various T cells. Here, we show that the IL-2-stimulated phosphorylation is mediated by the IL-2R beta-chain composed of the high affinity IL-2R, and induced by activation of Ca2+/phospholipid-dependent protein kinase C (PKC). The IL-2-stimulated phosphorylation was always observed in various T cell lines bearing high affinity IL-2R, but never observed in cells which express only low affinity IL-2R consisted of alpha-chain alone. When the expression of high affinity IL-2R was modified by anti-IL-2R mAb for reducing the affinity to 8- to 10-fold lower without affecting the sites of IL-2R, the effective dose of IL-2 on phosphorylation of pp67 increased 8 to 10 times. When cells were treated with pronase, approximately 95% sites of low affinity IL-2R were selectively decreased, but the IL-2 dose dependency for pp67 phosphorylation was little affected. These data exactly suggest that protein phosphorylation in response to IL-2 such as pp67 and pp63s, is mediated by high affinity but not low affinity IL-2R. Furthermore, the IL-2-stimulated phosphorylation of these proteins was also observed in MLA 144 cells which express only low affinity IL-2R consisting of beta-chain alone. In addition, various phorbol esters and tumor promoters, which activate PKC, were also demonstrated to induce the phosphorylation of a pp67 and pp63s in these T cell lines. Therefore, the present study suggests that IL-2/IL-2R beta-chain interaction triggers the phosphorylation of pp67 and pp63s, where the PKC may have an important role.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3132502

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

1.  Interleukin 2, soluble interleukin 2 receptor, and interferon-gamma in the suction blister fluids from psoriatic skin.

Authors:  H Takematsu; H Tagami
Journal:  Arch Dermatol Res       Date:  1990       Impact factor: 3.017

2.  Ligand-stimulated tyrosine phosphorylation of the IL-2 receptor beta chain and receptor-associated proteins.

Authors:  D A Shackelford; I S Trowbridge
Journal:  Cell Regul       Date:  1991-01

3.  T-lymphocyte interleukin 2-dependent tyrosine protein kinase signal transduction involves the activation of p56lck.

Authors:  I D Horak; R E Gress; P J Lucas; E M Horak; T A Waldmann; J B Bolen
Journal:  Proc Natl Acad Sci U S A       Date:  1991-03-01       Impact factor: 11.205

4.  Sequential effects of interleukin 2-diphtheria toxin fusion protein on T-cell activation.

Authors:  G Walz; B Zanker; K Brand; C Waters; F Genbauffe; J B Zeldis; J R Murphy; T B Strom
Journal:  Proc Natl Acad Sci U S A       Date:  1989-12       Impact factor: 11.205

5.  Effects of p56lck deficiency on the growth and cytolytic effector function of an interleukin-2-dependent cytotoxic T-cell line.

Authors:  L Karnitz; S L Sutor; T Torigoe; J C Reed; M P Bell; D J McKean; P J Leibson; R T Abraham
Journal:  Mol Cell Biol       Date:  1992-10       Impact factor: 4.272

6.  Interleukin 2 induces tyrosine phosphorylation and activation of p72-74 Raf-1 kinase in a T-cell line.

Authors:  B Turner; U Rapp; H App; M Greene; K Dobashi; J Reed
Journal:  Proc Natl Acad Sci U S A       Date:  1991-02-15       Impact factor: 11.205

7.  Monoclonal antibody defining a molecule possibly identical to the p75 subunit of interleukin 2 receptor.

Authors:  T Takeshita; Y Goto; K Tada; K Nagata; H Asao; K Sugamura
Journal:  J Exp Med       Date:  1989-04-01       Impact factor: 14.307

8.  Increased expression of the interleukin 2 (IL-2) receptor beta chain (p70) on CD56+ natural killer cells after in vivo IL-2 therapy: p70 expression does not alone predict the level of intermediate affinity IL-2 binding.

Authors:  S D Voss; R J Robb; G Weil-Hillman; J A Hank; K Sugamura; M Tsudo; P M Sondel
Journal:  J Exp Med       Date:  1990-10-01       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.